GroPep names new CEO
02 September, 2002 by Iain ScottAdelaide-based biotech GroPep has named former Faulding Pharmaceuticals top brass Robert Finder as its new CEO.
Auspep aiming to ride the big waves
29 August, 2002 by Pete YoungAustralian peptide maker Auspep is looking for funds to finance its growth on the back of a market that is jagging upward.
Novogen subsidiary to team with Yale in cancer drug trial
29 August, 2002 by Melissa TrudingerMarshall Edwards Inc (MIE), a subsidiary of Australian pharma Novogen, has announced an agreement with Yale University's Department of Obstetrics and Gynaecology that will allow the Yale researchers to take the company's anti-cancer drug phenoxodiol into clinical trials for ovarian cancer.
GroPep sales up, tips new CEO next week
28 August, 2002 by Iain ScottAdelaide biotech GroPep has blamed the Sydney operations it took over when it acquired Biotech Australia earlier this year for most of the $6.89m loss it sustained in the 2001-02 financial year.
NHMRC kicks off new development funding scheme
28 August, 2002 by Melissa TrudingerThe National Health and Medical Research Council has awarded more than $5 million to 15 researchers seeking to commercialise their discoveries, in the first round of its new development grant scheme.
CK Life mulling state sweeteners
28 August, 2002 by David BinningHong Kong's Cheong Kong Holdings-backed biotech venture CK Life Sciences is yet to decide which state will house its Australian operations, the company said on Tuesday, as it weighs up offers from some very determined suitors.
Metabolic gets good results on obesity drug
27 August, 2002 by Melissa TrudingerMetabolic Pharmaceuticals has achieved another milestone in its development of a weight-loss drug after demonstrating that its obesity drug AOD 9604 is active after oral administration to human patients.
Investment feature: the world's a stage
27 August, 2002 by Pete YoungDrugs, vaccines, diagnostics and devices are the hotspots of the global biomedical market that Australia's biotech researchers are scrambling to fill with products.
ResMed launches lawsuit against competitor
27 August, 2002 by Pete YoungSleep care company ResMed is living up to a reputation for aggressively defending its market position by launching a US patent infringement lawsuit against competitor Fisher and Paykel Healthcare.
Griffith has high hopes for patient monitor
26 August, 2002 by Claire DobleResearchers at Griffith University have developed a new method that monitors patients' vital signs, and sends a message to doctors if there is a problem.
Genetic Solutions beefed up by BIF grant
23 August, 2002 by Pete YoungAgri-tech company Genetic Solutions will use a $250,000 Biotech Innovation Fund (BIF) grant to ride herd on a database holding more than one million samples of livestock DNA.
We've paid the price, now let us work: Amrad boss
23 August, 2002 by Melissa TrudingerGently suggesting that analysts and investors should back off and let Amrad focus on its product development, managing director Sandra Webb presented Amrad as a case study on maturing public biotechnology companies at the AusBiotech 2002 conference.
CSIRO aims to strengthen its biotech focus
22 August, 2002 by Melissa TrudingerCSIRO has launched a biotechnology strategy in an attempt to strengthen its focus in the field.
Progen teams with CSIRO in manufacturing deal
20 August, 2002 by Pete YoungAustralia's largest contract drug manufacturer, Progen Industries, and CSIRO are marrying their bio-manufacturing skills.
Contract research organisations: labs for hire
19 August, 2002 by Pete YoungAs Australia's burgeoning young biotech hopefuls push toward clinical trials of their fledgling products, contract research organisations (CROs) are hoping for a rush of new business.
